investorscraft@gmail.com

Intrinsic value of Fate Therapeutics, Inc. (FATE)

Previous Close$25.00
Intrinsic Value
Upside potential
Previous Close
$25.00

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh5.88 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %77.7NaN
Revenue, $56NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m273NaN
Operating income, $m-217NaN
EBITDA, $m-211NaN
Interest expense (income), $mNaN
Earnings before tax, $m-216NaN
Tax expense, $m-4NaN
Net income, $m-212NaN

BALANCE SHEET

Cash and short-term investments, $m616NaN
Total assets, $m921NaN
Adjusted assets (=assets-cash), $m306NaN
Average production assets, $m160NaN
Working capital, $m552NaN
Total debt, $m115NaN
Total liabilities, $m243NaN
Total equity, $m679NaN
Debt-to-equity ratio0.169NaN
Adjusted equity ratio0.224NaN

CASH FLOW

Net income, $m-212NaN
Depreciation, amort., depletion, $m6NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-163NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-51NaN
Free cash flow, $m-112NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m552
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount